Summary: The FDA recently issued a suite of six guidance documents, which will be the building blocks of an up to date and more comprehensive framework to ensure the advancement of the field of cell and gene...
Summary: Alberto Santagostino, Lonza's SVP Cell and Gene Technologies delivers an invigorating keynote presentation at Phacilitate Leaders World Miami where he explores the considerations and potential of...
Summary:
The FDA introduced the ‘Regenerative Medicine Advanced Therapy Designation’ as part of the USA’s 21st Century Cures act of 2016, with the aim of accelerating product approvals.
So, what is the FDA...
Summary: This episode is the first in our series of Women in Advanced Therapies interviews, where we'll be talking to a selection of the women featured in the '11Most Influential Women in Advanced Therapies'...
Summary: One of Aristotle’s most famous musings has stood the test of time; the whole is indeed greater than the sum of its parts.
This profound statement is never truer than when applied to advanced...
Summary: Professor Marc Turner, Professor of Cellular Therapy and Medical Director, Scottish National Blood Transfusion Service and Dr Maria Pia Cicalese, IRCCS San Raffaele discuss the reality of delivering...
Summary: Healthcare infrastructure and the patient journey are increasingly important factors for our industry. The delivery of advanced therapy treatments requires highly specialised skillsets and technology...
Summary: Nicole Gularte is a patient advocate who has undergone CAR-T therapy, not once but twice, chronicling her journey on her blog Fight for Cures. In this episode of Phacilitate:TALKS, Nicole bravely...
Summary: We spoke to Sean Werner, President Sexton Biotechnologies about embedding flexibility into automated bioprocessing, especially for early-stage biotechs.
Sean discusses the main advantages of...
Summary: In this episode, hosts Anthony Davies and Michael Adeniya get to talk to two cell therapy CMC experts in Delfi Krishna, Director Cell and Gene Therapy Platform: R&D Strategy at GSK and Jacob...
